Submission of Earnings Presentation on Audited Financial Results for the quarter and year ended March 31, 2025.
Awaiting price reaction for this filing.
Aurobindo Pharma reported its highest-ever quarterly revenue of ₹8,382 Cr in Q4FY25, up 10.6% year-on-year and 5.1% quarter-on-quarter. EBITDA came in at ₹1,792 Cr (margin of 21.4%, slightly down from 22.3% YoY but up from 20.4% QoQ), while net profit stood at ₹903 Cr, up 6.7% QoQ. For full-year FY25, revenue grew 9.4% YoY to ₹31,724 Cr and net profit rose 9.9% YoY to ₹3,486 Cr, with EPS at ₹59.81 (up 10.4%). The company swung to a net cash position of ~US$ 42 Mn as of March 2025, from a net debt of US$ 84 Mn in December 2024. In the US, it filed 9 ANDAs, received 5 approvals, and launched 5 products in Q4, while outlining an expanding biosimilars pipeline with first US FDA submission planned for FY26.
Record quarterly revenue, improving full-year margins, and a return to net cash highlight operational strength and debt reduction, which are positive for shareholders. Continued US ANDA filings and biosimilars progress support long-term growth visibility, though EBITDA margin compression YoY remains a watch point.